The HSE is assessing this medicine in line with the criteria detailed in legislation. It is important to say that the company which markets this medication submitted the document ten months after the health technology assessment, HTA, was commissioned by the HSE. There has been substantial delay in relation to this. We received a commercial proposal on 27 May and the drugs group is meeting in July, as it does, bringing together the scientists involved to assess the effectiveness of the medication and the cost toget…